Intellectual Property and Trade
June 19, 2012
|
June 18, 2012
|
March 29, 2011
|
July 1, 2005
|
Letters, Testimony & Comments
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products. Peru is a growing market for biotechnology products and with the implementation of the US-Peru TPA, it promises to become an even bigger market.
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of biological origin. Many elements of the third draft appear to have addressed BIO's previous comments with respect to clarity of structure and definitions of terms, as well as expectations for data requirements.
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.
February 1 2013
BIO respectfully submits both questions and comments for the National Health Surveillance Agency’s (ANVISA) consideration on the proposed rules. BIO appreciates ANVISA’s desire to clarify their role in the review of patent applications for pharmaceutical products and processes.
January 18 2013
The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide comments in response to the Controller General of Patents Designs and Trademarks in India on the "Draft Guidelines for Examination of Biotechnology Applications" hereafter referred to as "Draft Guidelines", or "Guidelines".
Press Releases
February 21 2011
Want to learn more about the biotech industry?
Business Solutions Sponsor
